Eran R Andrechek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6549349/publications.pdf

Version: 2024-02-01

37 papers	1,676 citations	304602 22 h-index	345118 36 g-index
43 all docs	43 docs citations	43 times ranked	3436 citing authors

#	Article	IF	Citations
1	E2F Transcription Factors in Cancer, More than the Cell Cycle. , 2021, , .		1
2	Metastasis is altered through multiple processes regulated by the E2F1 transcription factor. Scientific Reports, 2021, 11, 9502.	1.6	3
3	Studying Lymphatic Metastasis in Breast Cancer: Current Models, Strategies, and Clinical Perspectives. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 191-203.	1.0	18
4	Low E2F2 activity is associated with high genomic instability and PARPi resistance. Scientific Reports, 2020, 10, 17948.	1.6	6
5	Integrated analyses of murine breast cancer models reveal critical parallels with human disease. Nature Communications, 2019, 10, 3261.	5.8	43
6	E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration. Scientific Reports, 2019, 9, 10718.	1.6	54
7	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 2019, 10, 2901.	5.8	24
8	Functional Redundancy between Î²1 and Î²3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. Cell Reports, 2019, 29, 589-602.e6.	2.9	35
9	Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Reports, 2019, 29, 249-257.e8.	2.9	29
10	How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 231-243.	1.0	7
11	Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. Nature Communications, 2019, 10, 2138.	5.8	58
12	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. Journal of Molecular Medicine, 2018, 96, 111-117.	1.7	6
13	Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Antioxidants and Redox Signaling, 2018, 29, 1535-1552.	2.5	31
14	Estrogen-regulated feedback loop limits the efficacy of estrogen receptorâ€“targeted breast cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7869-7878.	3.3	55
15	Transcription factor compensation during mammary gland development in E2F knockout mice. PLoS ONE, 2018, 13, e0194937.	1.1	17
16	Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. Breast Cancer Research, 2018, 20, 9.	2.2	23
17	Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers. PLoS Genetics, 2018, 14, e1007135.	1.5	54
18	Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2017, 22, 71-84.	1.0	17

#	Article	IF	Citations
19	Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics, 2017, 18, 1595-1609.	0.6	165
20	LPA receptor activity is basal specific and coincident with early pregnancy and involution during mammary gland postnatal development. Scientific Reports, 2016, 6, 35810.	1.6	9
21	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunology Research, 2016, 4, 600-610.	1.6	86
22	Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. Molecular and Cellular Biology, 2016, 36, 1509-1525.	1.1	53
23	Stat3 accelerates Myc induced tumor formation while reducing growth rate in a mouse model of breast cancer. Oncotarget, 2016, 7, 65797-65807.	0.8	9
24	Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation. Molecular Cell, 2015, 57, 95-107.	4.5	209
25	Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. Oncoscience, 2015, 2, 867-871.	0.9	16
26	Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget, 2015, 6, 38210-38224.	0.8	27
27	A genomic analysis of mouse models of breast cancer reveals molecular features ofmouse models and relationships to human breast cancer. Breast Cancer Research, 2014, 16, R59.	2.2	69
28	The E2F Transcription Factors Regulate Tumor Development and Metastasis in a Mouse Model of Metastatic Breast Cancer. Molecular and Cellular Biology, 2014, 34, 3229-3243.	1.1	103
29	Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc-Induced Tumors. Cancer Research, 2011, 71, 1924-1932.	0.4	48
30	Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. Journal of Molecular Medicine, 2010, 88, 1095-1100.	1.7	25
31	Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16387-16392.	3.3	81
32	Patterns of cell signaling pathway activation that characterize mammary development. Development (Cambridge), 2008, 135, 2403-2413.	1.2	43
33	Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene, 2005, 24, 932-937.	2.6	58
34	Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4984-4989.	3.3	22
35	Developmental timing of activated erbB2 expression plays a critical role in the induction of mammary tumors. Cell Cycle, 2004, 3, 1111-3.	1.3	2
36	Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Research, 2003, 63, 4920-6.	0.4	53

#	Article	IF	Citations
37	ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival. Molecular and Cellular Biology, 2002, 22, 4714-4722.	1.1	114